PubMed
Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin
Winbanks CE, Wang B, Beyer C, et al. American Journal of Physiology — Endocrinology and Metabolism. 2009
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 45% · Mixed 44% · Unfavorable overall 11%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 1–2 mg · Most common: 0.6–1 mg
Reports span 0.2–5 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 55% said they felt similar to their last entry, 31% more positive, and 15% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 20 days · Based on 236 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 50% · Mixed 34% · Unfavorable overall 16%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 200–400 mcg · Most common: 100–200 mcg
Reports span 25–1000 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 60% said they felt similar to their last entry, 42% more positive, and 20% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 25 days · Based on 131 repeat reporters
Published sources linked on the Follistatin 344 and Selank wiki pages.
PubMed
Winbanks CE, Wang B, Beyer C, et al. American Journal of Physiology — Endocrinology and Metabolism. 2009
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Sugiyama M, Yamaki A, Furuya M, et al. American Journal of Physiology — Endocrinology and Metabolism. 2010
PubMed
Sepulveda PV, Bush ED, Bhattacharya A, et al. Scientific Reports. 2015
PubMed
Stefanakis K, Kokkorakis M, Mantzoros CS. Metabolism: clinical and experimental. 2024
PubMed
Ershov FI, Uchakin PN, Ershova OV. Bull Exp Biol Med. 2017
PubMed
Seredenin SB, Kozlovskaya MM. Bull Exp Biol Med. 2008
PubMed
Ershov FI, Uchakin PN. Bull Exp Biol Med. 2010
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Panikratova YR, Lebedeva IS, Sokolov OY, et al. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections. 2020
PubMed
Konstantinopolsky MA, Chernyakova IV, Kolik LG. Bulletin of experimental biology and medicine. 2022